Abbas Hajifathali

Abbas Hajifathali

Auto-generated profile, based on publicly available information

Abbas Hajifathali

Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MBMehdi Bakhtiyaridovvombaygi
Mehdi Bakhtiyaridovvombaygi
SYSomayeh Yazdanparast
Somayeh Yazdanparast
FMFatemeh Mikanik
Fatemeh Mikanik
AIAmirhossein Izadpanah
Amirhossein Izadpanah
SPSahar Parkhideh
Sahar Parkhideh
AGAhmad Gharehbaghian
Ahmad Gharehbaghian
Acute myeloid leukemia (AML) is a heterogeneous disease developed from the malignant expansion of myeloid precursor cells in the bone marrow and peripheral blood. The implementation of intensive chemotherapy and hematopoietic stem cell transplantation (HSCT) has improved outcomes associated with AML, but relapse, along with suboptimal outcomes, is still a common scenario. In the past few years, exploring new therapeutic strategies to optimize treatment outcomes has occurred rapidly. In this regard, natural killer (NK) cell-based immunotherapy has attracted clinical interest due to its critical role in immunosurveillance and their capabilities to target AML blasts. NK cells are cytotoxic innate lymphoid cells that mediate anti-viral and anti-tumor responses by producing pro-inflammatory cytokines and directly inducing cytotoxicity. Although NK cells are well known as short-lived innate immune cells with non-specific responses that have limited their clinical applications, the discovery of cytokine-induced memory-like (CIML) NK cells could overcome these challenges. NK cells pre-activated with the cytokine combination IL-12/15/18 achieved a long-term life span with adaptive immunity characteristics, termed CIML-NK cells. Previous studies documented that using CIML-NK cells in cancer treatment is safe and results in promising outcomes. This review highlights the current application, challenges, and opportunities of CIML-NK cell-based therapy in AML.

7 May 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AHAbbas Hajifathali
Abbas Hajifathali
SPSayeh Parkhideh
Sayeh Parkhideh
MKMohammad H. Kazemi
Mohammad H. Kazemi
RCRouzbeh Chegeni
Rouzbeh Chegeni
ERElham Roshandel
Elham Roshandel
MGMajid Gholizadeh
Majid Gholizadeh

15 November 2022 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
ERElham Roshandel
Elham Roshandel
MMMaryam Mehravar
Maryam Mehravar
MNMaryam Nikoonezhad
Maryam Nikoonezhad
AAAfshin Mohammad Alizadeh
Afshin Mohammad Alizadeh
MMMohammad Majidi
Mohammad Majidi
AHAbbas Hajifathali
Abbas Hajifathali

1 January 2022 in Leukemia Research
Verified
Journal Article
Closed access
RMReza Mirfakhraie
Reza Mirfakhraie
LNLeila Noorazar
Leila Noorazar
MMMozhdeh Mohammadian
Mozhdeh Mohammadian
AHAbbas Hajifathali
Abbas Hajifathali
MGMajid Gholizadeh
Majid Gholizadeh
MMMahshid Mehdizadeh
Mahshid Mehdizadeh

2 March 2020 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
KGKatayoon Ghasemi
Katayoon Ghasemi
SPSayeh Parkhideh
Sayeh Parkhideh
MKMohammad Hossein Kazemi
Mohammad Hossein Kazemi
MSMaryam Salimi
Maryam Salimi
SSSina Salari
Sina Salari
AHAbbas Hajifathali
Abbas Hajifathali
Background: Uric acid (UA) level is of the valuable signs of inflammation. However, the role of UA in the outcomes of hematopoietic stem cell transplantation (HSCT) such as GVHD and patients’ overall survival is still a matter of debate. In this study, we aimed to evaluate the relationship between UA levels and GVHD incidence and overall survival in allogeneic HSCT patients.Methods: A total of 201 patients who were admitted for allogeneic transplantation at Taleghani hospital, Tehran, Iran, were considered for retrospective analysis. Serum UA levels from 1 week before transplantation until 2 weeks after transplantation were used to determine thresholds and find out the association of serum UA levels with GVHD and overall survival.Results: We showed that the determined thresholds using receiver operating characteristic curves have poor predictive value for GVHD and overall survival. The patients with serum UA higher than 3.4 mg/dL had 37% lower odds of GVHD incidence and 35% lower hazard of death than patients with UA lower than 3.4 mg/dL.Conclusion: Our results indicated that serum UA levels lower than 3.4 mg/dL could significantly increase the incidence of GVHD and hazard of death. The antioxidant functions of UA could explain the lower incidence of GVHD in hyperuricemic patients. However, the inconsistencies of the previous studies require further investigation to elucidate the role of UA in the prediction of GVHD.

29 October 2022 in Clinical Immunology
Verified
Journal Article
Closed access
ERElham Roshandel
Elham Roshandel
HGHaniyeh Ghaffari-Nazari
Haniyeh Ghaffari-Nazari
MMMozhdeh Mohammadian
Mozhdeh Mohammadian
MSMaryam Salimi
Maryam Salimi
SASaeid Abroun
Saeid Abroun
AHAbbas Hajifathali
Abbas Hajifathali